Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in adverse effects/events: extrapyramidal symptoms ‐ + haloperidol ‐… compared with same enzodiazepines (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines + antipsychotics changes tranquillisation or asleep: sedation ‐ medium term ‐ +/vs… compared with same antipsychotics (very low certainty).
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in global state: no improvement ‐ +/vs haloperidol ‐ medium term As… compared with same antipsychotics (low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in adverse effects/events: extrapyramidal symptoms ‐ +/vs haloperidol ‐… compared with same antipsychotics (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · psychosis‐induced aggression or agitation
Benzodiazepines showed no clear difference in tranquillisation or asleep: sedation ‐ medium term vs haloperidol… compared with antipsychotics (low certainty).
1 finding from 1 review
Global state: no improvement ‐ vs haloperidol ‐ medium term As defined in each study · psychosis‐induced aggression or agitation
Benzodiazepines showed no clear difference in global state: no improvement ‐ vs haloperidol ‐ medium term As… compared with antipsychotics (low certainty).
1 finding from 1 review
Intervention not reported
Severity of delirium (binary severe vs. not severe) Number of patients requiring greater than 3mg of haloperidol
The intervention showed no clear difference in severity of delirium (binary severe vs. not severe) Number of… (moderate certainty).
1 finding from 1 review
Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Global state: Changing dose because of deterioration ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Changing dose because of deterioration ‐ switching to… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review
Mental state: Deteriorated ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in mental state: Deteriorated ‐ switching to haloperidol decanoate from… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review
Length of delirium episode · adult AIDS patients with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of delirium · adult AIDS patients with delirium
1 finding from 1 review
Any adverse event ESRS, higher = worse · adult AIDS patients with delirium
1 finding from 1 review
Duration of hospital admission (days) · adult AIDS patients with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality from all causes · adult AIDS patients with delirium
It is very uncertain whether benzodiazepines (lorazepam) changes mortality from all causes compared with antipsychotics (haloperidol) (very low certainty).
1 finding from 1 review
Efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score by end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania
1 finding from 1 review
Remission · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Acceptability: total withdrawals · acute mania
It is very uncertain whether lithium changes acceptability: total withdrawals compared with haloperidol (very low certainty).
1 finding from 1 review
Adverse events · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found